Jonathan Weller
LMU Klinikum · 83 works · 810 citations · h-index 14
Top works
- Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
- Glycolysis and the pentose phosphate pathway are differentially associated with the dichotomous regulation of glioblastoma cell migration versus proliferation
- The value of visible 5-ALA fluorescence and quantitative protoporphyrin IX analysis for improved surgery of suspected low-grade gliomas
- Interstitial Photodynamic Therapy Using 5-ALA for Malignant Glioma Recurrences
- Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas
- Response properties of the genetically encoded optical H2O2 sensor HyPer
- TSPO PET signal using [18F]GE180 is associated with survival in recurrent gliomas
- PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression
- The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects
- Extended stereotactic brain biopsy in suspected primary central nervous system angiitis: good diagnostic accuracy and high safety
- MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial
- Extent and prognostic value of MGMT promotor methylation in glioma WHO grade II
- Dorsal column mapping in resection of intramedullary spinal cord tumors: a prospective comparison of two methods and neurological follow-up
- Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma
- Extent, pattern, and prognostic value of MGMT promotor methylation: does it differ between glioblastoma and IDH-wildtype/TERT-mutated astrocytoma?
- Limited efficacy of temozolomide alone for astrocytoma, IDH-mutant, CNS WHO grades 2 or 3
- Neurosurgical resection of multiple brain metastases: outcomes, complications, and survival rates in a retrospective analysis
- Determinants of long-term survival in patients with IDH-mutant gliomas
- The value of stereotactic biopsy of primary and recurrent brain metastases in the era of precision medicine
- Treatment benefit in patients aged 80 years or older with biopsy-proven and non-resected glioblastoma is dependent on MGMT promoter methylation status